Business Context and Reporting Period
PDS Biotechnology Corporation (PDSB) filed a Form 8-K on July 30, 2026, regarding a regulatory notice from The Nasdaq Stock Market LLC. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price status relative to Nasdaq listing requirements.
Material Changes
The Company received a deficiency letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of its common stock has been below the minimum $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). This deficiency has no immediate effect on the listing status, and trading continues under the symbol "PDSB."
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial 180-day compliance period ending January 26, 2027, to regain compliance.
- Regaining Compliance: To receive written confirmation of compliance, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within the compliance period.
- Future Options: If the Company fails to regain compliance by the deadline, it may be eligible for a second 180-day compliance period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency.
- Delisting Risk: Failure to regain compliance by the end of the applicable compliance period will result in the Company's common stock becoming subject to delisting. The Company retains the right to appeal a delisting determination to a hearings panel.
- Management Action: Management intends to monitor the stock price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of PDSB stock to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential execution of a reverse stock split.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first is unsuccessful.
- Track the stock price performance leading up to the January 26, 2027, deadline.